Streetbeat News

Products Services

MRKR

Marker Therapeutics, Inc. has received approval for the nonproprietary name 'Neldaleucel' for its product MT-601 from the United States Adopted Name Council and the International Nonproprietary Names Expert Committee. This marks a step forward in the development and potential commercialization of MT-601.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 12:46 pm

NUKK

Nukkleus Inc. (NASDAQ:NUKK) and its subsidiary, Digital RFQ (DRFQ), have announced a collaboration with Tantel Group to expand in Africa's B2B payments market, valued at over $1.5 trillion. The partnership aims to improve cross-border payment efficiency, reduce costs, and enhance reliability in the region. Nukkleus's CEO emphasized the potential for increased transaction volume for DRFQ as a result of this initiative.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 12:46 pm

SRDX

Surmodics has announced the early clinical use of its Pounce LP Thrombectomy System, which received FDA clearance in June 2023. The system is in limited market evaluation with a full commercial launch expected after the LME is completed.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 12:41 pm

RVSN

Rail Vision announced that its Main Line System has successfully received formal certifications for key EU railway standards. Noam Shloper, Head of Quality and Reliability, stated this achievement positions the company ahead of its competitors in the railway technology market.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 12:39 pm

APYX

Apyx Medical announced the publication of a peer-reviewed article in the Aesthetic Surgery Journal Open Forum. The article evaluated the use of Renuvion, a proprietary technology of Apyx Medical, for contracting subcutaneous soft tissue following liposuction in multiple areas of the body.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 12:38 pm

PMN

ProMIS Neurosciences has chosen PMN400 as its lead vaccine candidate to target multiple synucleinopathies, including Multiple System Atrophy, Parkinson's Disease, and Lewy Body Dementia.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 12:35 pm

ACIU

RHHBY

AC Immune SA will regain all global rights to its Alzheimer's treatment candidates, crenezumab and semorinemab, after the termination of its collaboration agreements with Genentech, a member of the Roche group. This follows Genentech's decision to return the rights to AC Immune, which could impact the future development and potential commercialization of these drugs.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 12:33 pm

CARA

Cara Therapeutics is reallocating its resources to concentrate on the oral difelikefalin Phase 2/3 program for treating notalgia paresthetica. The company is also reducing its operating expenses, which will extend its cash runway into 2026.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 12:30 pm

ATHE

Alterity Therapeutics, a biotech company focusing on neurodegenerative diseases, has issued a shareholder letter detailing their 2023 achievements and 2024 goals. They reported hitting all 2023 milestones, particularly in Multiple System Atrophy (MSA) research. Their lead candidate, ATH434, has shown promise in pre-clinical studies and has been granted Orphan Drug Designation by the U.S. FDA and the European Commission. Two Phase 2 trials are underway, with topline results from the ATH434-201 study expected in January 2025 and preliminary data from the ATH434-202 study expected in the first half of 2024. Promising data from a Parkinson's disease primate model was also presented, supporting the potential of ATH434 in treating Parkinson's disease.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 12:29 pm

DORM

Dorman Products, Inc. has launched over 3,000 new products in 2023 and is starting the new year with an announcement of 325 new motor vehicle parts. This expansion of their product line could indicate a focus on growth and meeting market demand for vehicle parts.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 12:28 pm